Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Infor	rmation and documents given to ASX bec	ome ASX's property and may be i	made public.	
	e of entity ma Pharmaceuticals Limited	ABN/ARSN 15 088 417 403		
We	(the entity) give ASX the following	ng information.		
Inf	ormation about buy-back			
1	Type of buy-back	On-market buy-back		
2	Date Appendix 3C was given to ASX	13 September 2012		
	tal of all shares/units be eptances have been recei	ved, before, and on,	previous day	
		Before previous day	Previous day	
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	5,318,280	201,371	
4	Total consideration paid or payable for the shares/units	\$3,406,799	\$133,086	

			Before previous day			Previous day		
5	If buy-back is an obuy-back	on-market	Highest \$0.6700	price	paid:	Highest \$0.6650	price	paid:
						Lowest \$0.6550	price	paid:
			Lowest \$0.6250	price	paid:	Highest under \$0.6773	price al rule	lowed 7.33:

## How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

113,110,701			

## Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

(Director/Company secretary)

Date: 23 October 2012

Print name: SUE MORGAN